To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.
Also called NCT05814406
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 196 participants
- Sponsor
- Registry
-
NCT05814406
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05814406. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-12 (actual); primary completion 2024-03-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- JW0201
- Intervention (Drug)
- Placebo
- Lead sponsor
- JW Pharmaceutical
Record details
- Record id
cardio:ct-nct05814406- Content hash
e7e3cb22465c99ad1222292dd3f7c595b42b0262fb878db1510e834b5a6ed09f